Upon joining the study, you will attend an initial visit. During this visit, you will undergo a series of assessments to confirm your eligibility for the trial. This includes a review of your medical history and a comprehensive eye examination.

If you are a female participant of childbearing potential, a pregnancy test will be conducted to ensure eligibility. You will also be required to agree to use an acceptable method of contraception during the study and for 30 days after the last dose of the study drug.

After confirming eligibility, you will be randomly assigned to one of the study groups. This means you will receive either EYE103 or ranibizumab (also known as Lucentis).

The first dose of the study medication will be administered through an injection into the eye, a procedure known as intravitreal use. The dosage for EYE103 will be either 0.5 mg or 0.8 mg, while ranibizumab will be administered at a dose of 0.5 mg.

You will attend regular follow-up visits throughout the study period, which lasts up to 52 weeks. These visits are crucial for monitoring your response to the treatment and ensuring your safety.

During these visits, your vision will be assessed using a standardized chart to measure any changes in your visual acuity. This is known as the ETDRS chart, which stands for Early Treatment of Diabetic Retinopathy Study.

You will continue to receive the assigned study medication at regular intervals as determined by the study protocol. The frequency of these injections will be explained to you during your visits.

It is important to attend all scheduled appointments and follow the instructions provided by the study team to ensure the best possible outcomes.

At the end of the study period, a final assessment will be conducted. This will include a comprehensive eye examination and a review of your overall health status.

The primary goal of this assessment is to evaluate the change in your visual acuity from the start of the study to the end, using the ETDRS chart.